Sellas Life Sciences Group Inc (SLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 71,893 | 13,986 | 2,630 | 17,225 | 21,455 |
| TOTAL | $75,211 | $16,327 | $3,172 | $17,756 | $23,044 |
| Non-Current Assets | |||||
| Intangibles | 1,914 | 1,914 | 1,914 | 1,914 | 1,914 |
| Other Non-Current Assets | 1,220 | 1,191 | 1,133 | 1,273 | 1,317 |
| TOTAL | $3,134 | $3,105 | $3,047 | $3,187 | $3,231 |
| Total Assets | $78,345 | $19,432 | $6,219 | $20,943 | $26,275 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,948 | 3,500 | 5,639 | 8,857 | 2,144 |
| Accrued Expenses | 3,525 | 5,466 | 7,650 | 6,286 | 2,640 |
| TOTAL | $7,017 | $9,510 | $13,735 | $15,515 | $4,982 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 457 | 457 | 460 | 577 | 946 |
| TOTAL | $457 | $457 | $460 | $577 | $946 |
| Total Liabilities | $7,474 | $9,967 | $14,195 | $16,092 | $5,928 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 179,583 | 90,847 | 56,268 | 28,303 | 15,906 |
| Common Shares | 15 | 7 | 3 | 2 | 2 |
| Retained earnings | -274,988 | -248,125 | -217,244 | -179,904 | -138,603 |
| TOTAL | $70,871 | $9,465 | $-7,976 | $4,851 | $20,347 |
| Total Liabilities And Equity | $78,345 | $19,432 | $6,219 | $20,943 | $26,275 |